Microbiome Modulation Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 4.19 Billion |
| Market Size (2030) | USD 6.82 Billion |
| CAGR (2025 - 2030) | 10.25% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Microbiome Modulation Market Analysis
The Microbiome Modulation Market size is estimated at USD 4.19 billion in 2025, and is expected to reach USD 6.82 billion by 2030, at a CAGR of 10.25% during the forecast period (2025-2030).
The major factors driving the market are the rising prevalence of gastrointestinal disorders, growing advancements in microbiome research, expanding applications, and rising strategic activities by the key players in the market.
Technological advancements in the development of novel microbiome modulation therapies are expected to increase the accessibility of these medications for the treatment of Clostridium difficile and Crohn's disease, ultimately driving the studied market over the forecast period.
For instance, in March 2024, The Crohn’s & Colitis Foundation in the United States announced that it had invested in three companies in the 2023 funding cycle of the IBD Ventures program. Aiming to accelerate the development of novel products, IBD Ventures directly invested in product-oriented research and development with the potential to improve remission rates and quality of life for patients with inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis. The source stated that these therapeutics span across diverse modalities, including two ventures in the microbiome realm. Hence, such developments accelerate technological advancements for the development of novel microbiome therapeutics, which ultimately drive the studied market over the forecast period.
Furthermore, the increasing research and development activities are expected to increase the launch of new microbiome modulation drugs in the market, which further drive the studied market over the forecast period. For instance, according to an article published by the Lancet Infectious Diseases Journal in December 2023, a randomized controlled trial in Hong Kong finds that the synbiotic drug SIM01 relieves multiple symptoms of long COVID, or post-acute COVID-19 syndrome (PACS). SIM01 contains strains of anaerobic bifidobacterium bacteria (which are probiotics) and soluble fibers (prebiotics) to alter the gut microbiome and possibly modify the immune response. Hence, such research activities increase the launch of novel microbiome modulation therapeutics and improve the accessibility of these drugs, which ultimately drive the studied market over the forecast period.
Moreover, the rising strategic activities, such as new product launches by key players, are also expected to increase the accessibility and affordability of microbiome therapeutics, which will ultimately drive the studied market over the forecast period. For instance, in April 2023, Seres Therapeutics, Inc., a microbiome therapeutics company, reported the United States Food and Drug Administration approval for Vowst, a fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI. Hence, the launch of such products is expected to increase the accessibility of microbiome therapeutics, which will ultimately drive the studied market over the forecast period.
Thus, the increasing technological advancements in the microbiome modulation field, growing research activities, and growing strategic activities by the key players in the market are expected to drive the studied market over the forecast period. However, lack of standardized products and competition from traditional therapies are expected to restrain the studied market over the forecast period.
Microbiome Modulation Market Trends
Gastrointestinal Diseases Segment is Expected to Hold Significant Market Share Over the Forecast Period
Gastrointestinal diseases such as Clostridium difficile infections, irritable bowel syndrome (IBS), Crohn's disease, and ulcerative colitis can be effectively treated by using microbiome modulation therapeutics. The major factors driving the segment are the rising prevalence of infectious diseases and growing strategic activities such as new product launches by key players.
The rising prevalence of gastrointestinal diseases, such as Clostridium difficile infections (CDI), is expected to increase the demand for microbiome modulation therapeutics for the effective management of these bacteria and reduce the total healthcare cost in hospital-acquired infections, which further drives the studied market over the forecast period.
For instance, according to an article published in BMC Infectious Disease in March 2023, Clostridioides difficile infection (CDI) affects approximately 500,000 patients annually in the United States. CDI carries significant burdens, including clinical, social, and economic. Clostridioides difficile infection (CDI) is the leading cause of antibiotic- and healthcare-associated infective diarrhea in the United States. Community-associated CDI is on the rise, almost doubling in the past decade, with an incidence of 63.3 cases per 100,000 persons in the country. Hence, the significant prevalence of clostridiodes difficile infection increases the demand for novel medicines such as microbiome therapeutics, which ultimately drive the studied market over the forecast period.
Furthermore, increasing strategic activities such as acquisitions, investments, and novel product approvals are expected to increase the accessibility of microbiome drugs, which further drive the demand for microbiome modulation therapies in the treatment of infectious diseases and accelerate the studied segment over the forecast period.
For instance, in March 2023, the United States Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI. Hence, the launch of such products in the market is expected to drive the studied market over the forecast period.
Thus, the increasing prevalence of infectious diseases and rising strategic activities, such as the launch of novel microbiome drugs that are used in the treatment of infectious diseases, are expected to increase the accessibility and affordability of microbiome modulation therapies, which ultimately drive the segment revenue over the forecast period.
North America is Expected to Hold the Significant Market Share Over the Forecast Period
The microbiome modulation market in North America is driven by factors such as the increasing prevalence of chronic diseases such as metabolic and endocrine disorders, advanced healthcare infrastructure, rising technological advancements, and increasing strategic activities such as acquisitions and new solutions launches are expected to drive the studied market over the forecast period.
The increasing prevalence of metabolic and endocrine disorders accelerates the research activities for the development of microbiome modulation therapies for the effective management of these diseases, which ultimately drive the studied market over the forecast period. For instance, according to the Centers for Disease Control and Prevention’s December 2023 updated data, around 35% of adults in the United States were affected by obesity in the previous year. Similarly, according to the Canadian Community Health Survey Report published in November 2023, around 8 million people in Canada are affected by obesity. It is also estimated that close to one in three Canadians aged 18 and older (30%) will be affected by obesity in 2024. Hence, the rising prevalence of chronic diseases such as obesity is expected to accelerate the research activities for the development of novel microbiome modulation therapeutics, which will ultimately drive the studied market over the forecast period.
Furthermore, the increasing technological advancement for the development of microbiome modulation therapeutics is also expected to increase the adoption of this medication in treating various diseases, which will further drive the studied market over the forecast period. For instance, according to an article published in the American Gastroenterological Association Journal in May 2024, there has been an increased ability to investigate the human microbiota through next-generation sequencing and functional assessment. This advancement has rapidly expanded the ability to study and modulate the gastrointestinal microbiome for treating gastrointestinal, hepatic, and extraintestinal conditions. Hence, the adoption of genomics in the development of precision microbiome therapeutics is expected to increase the launch of novel products in North America, which will ultimately drive the studied market over the forecast period.
Furthermore, rising strategic activities such as acquisitions and product launches by key players are also expected to drive the studied market over the forecast period. For instance, in May 2023, Creative Enzymes, which provides a variety of enzymes, probiotics, and extracts in the United States, reported the establishment of probiotic production and supply chain. The company is expected to use this production facility for the manufacturing of lactobacillus probiotics. Hence, such strategic activities by the key players in the market are expected to drive the studied market over the forecast period.
Hence, the increasing prevalence of chronic diseases such as obesity and diabetes, rising technological advancements, and increasing strategic activities such as new production facilities establishment by key players are expected to drive the studied market over the forecast period.
Microbiome Modulation Industry Overview
The microbiome modulation market is moderately fragmented due to the presence of many startups in the field. The major players in the market are adopting various strategic activities such as mergers, collaborations, and expansions to strengthen their geographical presence and expand their customer base across the globe. Investments in the startups that are developing microbiome therapeutics are increasing. Some of the key players in the market are Synlogics, Seres Therapeutics, Evofem Biosciences, Inc., Second Genome, and Microbiotica.
Microbiome Modulation Market Leaders
-
Synlogics
-
Seres Therapeutics
-
Evofem Biosciences, Inc.
-
Second Genome
-
Microbiotica
- *Disclaimer: Major Players sorted in no particular order
Microbiome Modulation Market News
- October 2024: Ixcela, the internal fitness company, in collaboration with Roper St. Francis Healthcare, reported the launch of the Ixcela Cancer Support Program. This initiative follows a landmark pilot program that demonstrates the transformative role of gut microbiome health in reducing the debilitating side.
- September 2024: EnteroBiotix, a Scottish biopharmaceutical company, received USD 21.5 million in investments from SIS Ventures and Kineticos Ventures in a series A round. The planned to use this funding advance its pipeline for multiple disease areas to enhance the gut microbiome.
Microbiome Modulation Industry Segmentation
As per the scope of the report, microbiome modulation is the practice of manipulating the microbiome in order to improve gut health and well-being. The microbiome modulation market is segmented into product, application, end-user, and geography. By product, the market is segmented into prebiotics, probiotics, synbiotics, and others. By application, the market is segmented into infectious diseases, gastrointestinal diseases, endocrine and metabolic disorders, and others. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers values (in USD) for the above segments.
| By Product | Prebiotics | ||
| Probiotics | |||
| Synbiotics | |||
| Others | |||
| By Application | Infectious Diseases | ||
| Gastrointestinal Diseases | |||
| Endocrine and Metabolic Disorders | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Microbiome Modulation Market Research FAQs
How big is the Microbiome Modulation Market?
The Microbiome Modulation Market size is expected to reach USD 4.19 billion in 2025 and grow at a CAGR of 10.25% to reach USD 6.82 billion by 2030.
What is the current Microbiome Modulation Market size?
In 2025, the Microbiome Modulation Market size is expected to reach USD 4.19 billion.
Who are the key players in Microbiome Modulation Market?
Synlogics, Seres Therapeutics, Evofem Biosciences, Inc., Second Genome and Microbiotica are the major companies operating in the Microbiome Modulation Market.
Which is the fastest growing region in Microbiome Modulation Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Microbiome Modulation Market?
In 2025, the North America accounts for the largest market share in Microbiome Modulation Market.
What years does this Microbiome Modulation Market cover, and what was the market size in 2024?
In 2024, the Microbiome Modulation Market size was estimated at USD 3.76 billion. The report covers the Microbiome Modulation Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Microbiome Modulation Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Microbiome Modulation Industry Report
Statistics for the 2025 Microbiome Modulation market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Microbiome Modulation analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
